Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States
Top Cited Papers
Open Access
- 9 May 2020
- journal article
- research article
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 14 (4), 813-821
- https://doi.org/10.1177/1932296820924469
Abstract
Diabetes has emerged as an important risk factor for severe illness and death from COVID-19. There is a paucity of information on glycemic control among hospitalized COVID-19 patients with diabetes and acute hyperglycemia. This retrospective observational study of laboratory-confirmed COVID-19 adults evaluated glycemic and clinical outcomes in patients with and without diabetes and/or acutely uncontrolled hyperglycemia hospitalized March 1 to April 6, 2020. Diabetes was defined as A1C ≥6.5%. Uncontrolled hyperglycemia was defined as ≥2 blood glucoses (BGs) > 180 mg/dL within any 24-hour period. Data were abstracted from Glytec’s data warehouse. Among 1122 patients in 88 U.S. hospitals, 451 patients with diabetes and/or uncontrolled hyperglycemia spent 37.8% of patient days having a mean BG > 180 mg/dL. Among 570 patients who died or were discharged, the mortality rate was 28.8% in 184 diabetes and/or uncontrolled hyperglycemia patients, compared with 6.2% of 386 patients without diabetes or hyperglycemia (P < .001). Among the 184 patients with diabetes and/or hyperglycemia who died or were discharged, 40 of 96 uncontrolled hyperglycemia patients (41.7%) died compared with 13 of 88 patients with diabetes (14.8%, P < .001). Among 493 discharged survivors, median length of stay (LOS) was longer in 184 patients with diabetes and/or uncontrolled hyperglycemia compared with 386 patients without diabetes or hyperglycemia (5.7 vs 4.3 days, P < .001). Among hospitalized patients with COVID-19, diabetes and/or uncontrolled hyperglycemia occurred frequently. These COVID-19 patients with diabetes and/or uncontrolled hyperglycemia had a longer LOS and markedly higher mortality than patients without diabetes or uncontrolled hyperglycemia. Patients with uncontrolled hyperglycemia had a particularly high mortality rate. We recommend health systems which ensure that inpatient hyperglycemia is safely and effectively treated.Keywords
This publication has 18 references indexed in Scilit:
- Does diabetes mellitus comorbidity affect in-hospital mortality and length of stay? Analysis of administrative data in an Italian Academic HospitalActa Diabetologica, 2017
- Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016Intensive Care Medicine, 2017
- Diabetic status and the relation of the three domains of glycemic control tomortality in critically ill patients: an international multicenter cohort studyCritical Care, 2013
- Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patientsCritical Care Medicine, 2012
- High glucose disrupts oligosaccharide recognition function via competitive inhibition: A potential mechanism for immune dysregulation in diabetes mellitusImmunobiology, 2010
- Methylglyoxal modulates immune responses: relevance to diabetesJournal of Cellular and Molecular Medicine, 2010
- Binding of SARS coronavirus to its receptor damages islets and causes acute diabetesActa Diabetologica, 2009
- Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARSDiabetic Medicine, 2006
- Hyperglycemia: An Independent Marker of In-Hospital Mortality in Patients with Undiagnosed DiabetesJournal of Clinical Endocrinology & Metabolism, 2002
- Immune dysfunction in patients with diabetes mellitus (DM)FEMS Immunology & Medical Microbiology, 1999